Cargando…

Toxicities associated with immune checkpoint inhibitors: a systematic study

Available evidence shows that the incidence of toxicities associated with cancer immunotherapy, such as programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1)-related toxicities, is estimated to be between 0.3 and 1.3%. OBJECTIVE: This systematic review aimed to investigate canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Xiangyi, Chen, Li, Su, Zhaohui, Sullivan, Ryan J., Blum, Steven M., Qi, Zhihong, Liu, Yulu, Huo, Yujia, Fang, Yi, Zhang, Lin, Gao, Jidong, Wang, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389211/ https://www.ncbi.nlm.nih.gov/pubmed/37132038 http://dx.doi.org/10.1097/JS9.0000000000000368

Ejemplares similares

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Potential role of gut microbes in the efficacy and toxicity of immune checkpoints inhibitors
por: Ma, Jingxin, et al.
Publicado: (2023)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
por: Yang, Fan, et al.
Publicado: (2023)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
por: Li, Yinuo, et al.
Publicado: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Imaging features of toxicities associated with immune checkpoint inhibitors
por: Gosangi, Babina, et al.
Publicado: (2022)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
por: Hughes, Michael S., et al.
Publicado: (2019)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
por: Pirozzi, Flora, et al.
Publicado: (2021)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
por: Chen, Ru, et al.
Publicado: (2021)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive
por: Gudiol, Carlota, et al.
Publicado: (2022)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
por: Yousif, Laura I., et al.
Publicado: (2023)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma
por: Zeng, Fan-li, et al.
Publicado: (2021)

How we treat neurological toxicity from immune checkpoint inhibitors
por: Spain, Lavinia, et al.
Publicado: (2019)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
por: Johnson, Douglas B., et al.
Publicado: (2019)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
por: Coureau, Michelle, et al.
Publicado: (2020)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis
por: Shieh, Christine, et al.
Publicado: (2021)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond
por: Gilon, Dan, et al.
Publicado: (2022)

Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management
por: Zarifa, Abdulrazzak, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8msrsge4bkeer40opec17e24o